Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects
Authors:
- Eef HoebenEHEef Hoeben
- Johan W. SmitJSJohan W. Smit
- David UpmalisDUDavid Upmalis
- Sarah RuschSRSarah Rusch
- Klaus SchafflerKSKlaus Schaffler
- Peter ReitmeirPRPeter Reitmeir
- Bernhard MangoldBMBernhard Mangold
- 1 August 2012
- journal article
- Published by Wolters Kluwer Health in Pain
- Vol. 153 (8) , 1648-1656
Abstract
TOC summary The analgesic/antihyperalgesic efficacy and dose-response relationship of 2 opioids was demonstrated in a human experimental algesimetric model using laser stimuli applied to sensitized skin. The aim of the study was to evaluate the analgesic/antihyperalgesic efficacy and to establish the dose-response relationship of morphine immediate release (IR) and oxycodone IR in a human experimental algesimetric model. Calculated effect ratios for peak-to-peak (PtP) amplitudes of laser-evoked potentials (LEPs) and visual analog scales (VAS) postlaser pain on UVB-irradiated skin (main target variables) were 1.68 and 1.18 respectively for oxycodone 10 mg/morphine 20 mg, 3.00 and 1.63 respectively for oxycodone 15 mg/morphine 30 mg, and 1.12 and 1.25 respectively for oxycodone 20 mg/morphine 40 mg. The effect on the laser-PtP amplitude of morphine at the highest dose (40 mg) and of oxycodone at all doses (10, 15, 20 mg) was considered to be clinically relevant based on a difference from placebo of ≥2.5 μV. For both compounds, a statistically significant linear trend was observed between dose groups in at least 1 of the 2 main target variables (adjusted P value for both end points <.001 at all doses). Hyperalgesia developed over time vs baseline due to acute exposure to UVB irradiation and to topical/occlusive 1% capsaicin solution. For both compounds, the principal onset of analgesic/antihyperalgesic drug effects was around 0.5 hours with an average peak at about 1 to 2 hours and the effect lasting for more than 3 hours (morphine 20 and 30 mg) or 6 hours (morphine 40 mg and oxycodone all doses). In conclusion, the study demonstrated a solid outcome of a mixed objective/subjective human experimental algesimetric model to approach dose-response relationships and analgesic/antihyperalgesic effects of 2 opioids.Keywords
This publication has 34 references indexed in Scilit:
- Predicting therapeutic efficacy — Experimental pain in human subjectsBrain Research Reviews, 2009
- Intradermal Capsaicin Causes Dose-Dependent Pain, Allodynia, and Hyperalgesia in HumansJournal of Investigative Medicine, 2006
- Peripheral Opioid Regulation of Nociceptors. Focus on “Morphine Directly Inhibits Nociceptors in Inflamed Skin”Journal of Neurophysiology, 2006
- Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain modelPain, 2005
- The Pharmacokinetics of OxycodoneJournal of Pain & Palliative Care Pharmacotherapy, 2005
- Spatial and temporal profiles of flare and hyperalgesia after intradermal capsaicinPain, 2003
- Clinical Pharmacokinetics of MorphineJournal of Pain & Palliative Care Pharmacotherapy, 2002
- Peripheral Antihyperalgesic Effect of Morphine to Heat, but Not Mechanical, Stimulation in Healthy Volunteers after Ultraviolet-B IrradiationAnesthesia & Analgesia, 1999
- The Human Capsaicin Model of Allodynia and HyperalgesiaJournal of Pain and Symptom Management, 1998
- Hypoalgesia following epidural morphine: a controlled quantitative experimental studyActa Anaesthesiologica Scandinavica, 1991